Immuno-modulatory Agents and Adjunctive Therapies for Severe Influenza

While early antiviral therapy is associated with improved outcome in patients hospitalized with seasonal influenza, antivirals alone are not sufficient to minimize morbidity and mortality from severe influenza. This review on “The role of adjuvant immunomodulatory agents for treatment of severe influenza” provides an update on the potential role of different immuno-modulatory agents and other adjunctive therapies in the management of patients hospitalized with severe influenza with a focus on the rationale and evidence for using these agents and their side effects (Antiviral Res. 2018 Jan 8;150:202-216. doi: 10.1016/j.antiviral.2018.01.002. [Epub ahead of print])
 
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof David Hui, Chairman of our Department of Medicine and Therapeutics. Prof Hui is an international expert in the clinical management of influenza and his research focuses on preventing nosocomial infections, sleep disordered breathing, and common airway diseases.
 
Full arcticle: http://www.sciencedirect.com/science/article/pii/S0166354217307362?via%3Dihub